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ABSTRACT  
The present study aims at investigating the mechanism by which MT4-MMP, a 
membrane-anchored MMP expressed by human breast tumor cells promotes the metastatic 
dissemination into lung. We applied experimental (intravenous) and spontaneous 
(subcutaneous) models of lung metastasis using human breast adenocarcinoma MDA-MB-231 
cells overexpressing or not MT4-MMP. We found that MT4-MMP does not affect lymph 
node colonization nor extravasation of cells from the bloodstream, but increases the 
intravasation step leading to metastasis. Ultrastructural and fluorescent microscopic 
observations coupled with automatic computer-assisted quantifications revealed that MT4-
MMP expression induces blood vessel enlargement and promotes the detachment of mural 
cells from the vascular tree, thus causing an increased tumor vascular leak. On this basis, we 
propose that MT4-MMP promotes lung metastasis by disturbing the tumor vessel integrity 





Several clinical and experimental investigations have indicated that breast cancer is an 
heterogeneous disease that could lead to a panel of proclivities, extending from a local disease 
to dissemination via lymphatic and/or hematogenous pathway [1]. A key feature of malignant 
cells is their ability to detach from the primary tumor and acquire migratory and invasive 
properties. To accomplish these goals, several proteolytic systems are used by cancer cells. 
The Matrix Metalloproteinases (MMPs) family of zinc dependent endopeptidases [2,3] 
represents one of the major protease families that have been associated with the progression 
of many cancers [4], including breast cancer [5,6], in which their role in tumor angiogenesis 
[7,8] and metastasis dissemination [9] has become evident. The MMP family includes 
secreted and membrane-anchored proteases [4]. Most of the Membrane Type-MMPs (MT-
MMPs) are transmembrane proteases (MT1-, MT2-, MT3-, MT5-MMP) [10] but two 
members are exceptionally linked to the membrane by a glycosyl-phosphatidylinositol (GPI) 
anchor (MT4-, MT6-MMP) [11]. Discovered almost a decade ago, the function and the role of 
these GPI-MT-MMPs in cancer remain largely elusive when compared to other MT-MMPs.  
MT4-MMP was originally cloned from a human breast carcinoma cDNA library 
[12,13] and has been detected in different organs including brain, colon, ovary, testis, uterus 
and lung [12-14]. The protein was also localized in inflammatory cells [11] and in several 
cancer cell lines [15] as well as in gliomas [16], prostate [17] and breast [12,18] carcinomas. 
MT4-MMP is unable to activate proMMP-2 and rather inefficient at hydrolyzing extracellular 
matrix (ECM) components compared to the other MT-MMPs [19]. Its catalytic domain is able 
to cleave in vitro very few substrates that include gelatin, fibrin(ogen), LRP, proTNF-alpha 
[19,20] and the aggrecanase ADAMTS-4 [21]. However, in MT4-MMP knock-out mice, 
neither proTNF-alpha shedding nor aggrecanalysis was affected by MT4-MMP depletion 
[14,22]. 
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In a previous work, we demonstrated a higher immunostaining of MT4-MMP in breast cancer 
cells rather than in normal breast epithelial cells from human tissue samples [18]. 
Furthermore, the overexpression of MT4-MMP in the breast cancer cell line MDA-MB-231 
enhanced subcutaneous tumor growth and most importantly led to lung metastasis when 
inoculated in RAG-1 immunodeficient mice [18]. However, no effect could be observed on 
proMMP-2 activation, VEGF production, angiogenesis nor cell migration and invasion in 
vitro. The unexpected tumor-promoting effect of MT4-MMP in vivo, together with its lack of 
effect on cancer cell invasion and proliferation in vitro suggest specific functions in the tumor 
microenvironment for this unconventional MT-MMP. Hence, to better understand the role of 
MT4-MMP, we applied histological methods and in vivo imaging to experimental 
(intravenous cell injection) or spontaneous (subcutaneous cell injection) models of metastasis. 
We provide evidence that MT4-MMP expression by cancer cells induce (i) an enlargement of 
blood vessels, (ii) a detachment of mural cells from the vascular tree and (iii) an increased 
tumor vascular leak. These effects of MT4-MMP promote hematogenous but not lymphatic 
dissemination of cancer cells by affecting the intravasation rather than the extravasation step 
of the metastatic cascade.  
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MATERIAL AND METHODS  
Cell culture 
Human breast cancer MDA-MB-231 cells were grown in Dulbecco’s Modifed Eagle’s 
Medium (DMEM) supplemented with 10% fetal calf serum (FCS), L-glutamine (2 mM), 
penicillin (100 U/ml) and streptomycin (100µg/ml) at 37°C in a 5% CO2 humid atmosphere. 
All culture reagents were purchased from Gibco-Life Technologies (Invitrogen Corporation, 
Paisley, Scotland). MDA-MB-231 cells stably expressing (MT4 clones) or not (CTR clones) 
MT4-MMP were obtained as previously described [18] by electroporation with pcDNA3-neo 
vector (Invitrogen) carrying the full-length human MT4-MMP cDNA or with a control empty 
vector, respectively. Three distinct clones stably expressing MT4-MMP and 3 control clones 
were maintained under basal pressure level of selection in medium containing 500 µg/ml of 
G418 (Life Technologies). For bioluminescent experiments, cells were transduced with 
lentiviruses encoding for firefly luciferase (Promega). Luciferase was checked to be expressed 
at same levels by incubation of cells in complete media supplemented with D-luciferin (150 
µg/ml, Promega) and by bioluminescent observation using a PhotonImager camera system 
(Biospace, France).  
 
Metastasis assays 
Metastatic potential of MDA-MB-231 cells expressing or not MT4-MMP was 
investigated with two distinct models of metastasis in immunodeficient mice : (i) a 
“spontaneous” model of lung metastasis from a subcutaneous (s.c.) primary tumor and (ii) an 
“experimental” model in which lung metastasis were directly induced by intravenous (i.v.) 
injection of the tumor cells. In the spontaneous model, tumor cells (1x106) were 
subcutaneously injected with matrigel (200 µl) in mice flank (n = 10) as previously described 
[18]. In the experimental metastasis model, cells were detached in PBS-EDTA 5 mM, 
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resuspended in serum-free medium (20x106 cells/ml) and injected (1x106 cells in 50 µl) into 
the lateral tail vein of the mice (n = 10). For each model of metastasis, either Rag-1 deficient 
mice or athymic nude mice (Charles River Laboratories, Lyon, France) were injected with 
tumor cells. Similar results were observed in both immunodeficient backgrounds. Metastases 
were detected 6 or 8 weeks after injection by histological, in vivo or ex vivo bioluminescence 
analyses.  
For histological analyses, paraffin-embedded organs were cut at 5 µm-thick and 
metastasis were detected by immunostaining for human Ki-67 protein as previously described 
[18]. The metastatic foci were counted in 45 histological fields per section at 200-fold 
magnification. The incidence of metastasis defines the percentage of mice with detectable Ki-
67 positive metastatic cells in the lung. The severity of metastasis characterizes the size of 
metastatic foci (number of Ki-67 positive cells per foci).  
For in vivo bioluminescence imaging of metastasis, nude mice were anesthetized with 
isofluorane (1-3%) and injected intraperitonealy with D-luciferin (Promega ; 150 mg/kg in 
PBS). Mice were then placed onto a warmed stage inside the light-tight camera box with 
continuous exposure to 1–2% isoflurane. Five mice were imaged at a time for 1-5 min of 
exposition to a PhotonImager optical camera (Biospace Lab, France). For ex vivo imaging, 
mice were sacrificed and tissues of interest were excised, placed into 24-well tissue culture 
plates containing D-luciferin (300 µg/ml in PBS) and imaged for 2 min. 
 
Lung extravasation assay 
 In order to assess the short-term extravasation of cells to the lungs of mice, cells were 
incubated for 30 min at 37°C in serum-free DMEM with 2.5 µM of red-fluorescent CMTPX 
CellTracker (Invitrogen, Molecular Probes, C34552), washed and reincubated in fresh serum-
free DMEM for another 30 min before being intravenously injected in nude mice as described 
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above (n = 10). After 48 hrs, mice were anesthetized by intraperitoneal injection of Nembutal 
(200 µl / mice) and their vasculature was labelled (modified protocol from [23]) by 
intracardiac injection of (FITC)-labelled Lycopersicon Esculentum (tomato) lectin (100 µg in 
100 µl 0.9% NaCl, Vector Laboratories, Burlingame, CA, FL-1171) which was allowed to 
circulate for 5 minutes. The pulmonary vasculature was then fixed by perfusion of 20 ml of 
paraformaldehyde 4% / PBS (PFA) through the right ventricle during 2 minutes whereas the 
blood / fixative mix was allowed to escape out of the lung vascular network by a small 
incision in the left atrium. Lungs were then harvested, fixed in 4% PFA at 4 °C for 1 hr, 
incubated in sucrose 30% / azide 0.1% / PBS at 4°C overnight, rinsed in PBS, frozen 
embedded in OCT compound (Tissue-Tek) and cut at 6 µm-thick with cryostat. Frozen 
sections were washed 3 times in PBS for 5 min, then dried at room temperature for 15 
minutes, counterstained and mounted with Vectashield Medium with DAPI (Vector 
Laboratories, Burlingame, CA, H-1200). FITC lectin-labelled vasculature was then analyzed 
by fluorescence microscopy at 400-fold magnification. Red CMTPX-labelled tumor cells 
remaining in the lungs after the perfusion were considered as extravasating tumor cells and 
counted in 20 microscopic optical fields.  
 
Histological and functional analysis of tumor lymphatic vessels 
Six weeks post cancer cell injection, tumor lymphatic vessels were visualized by 
immunostaining of 5-µm thick paraffin sections of xenografts using an anti-LYVE-1 rabbit 
polyclonal antibody (Upstate USA, Inc, Charlottesville, VA, ref. 07-538). To unmask 
antigens, slides were autoclaved for 11 min at 126°C in Target Retrieval Solution (Dako, 
S1699). Endogenous peroxidase was blocked by 3% H2O2 / H2O for 20 min and non-specific 
binding was prevented by incubation in PBS / BSA 10% (Fraction V, Acros Organics, NJ) for 
1 hr. Sections were then incubated with the anti-LYVE-1 antibody (1:1000) for 1 hr, with a 
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biotinylated second antibody (Dako, E0432, 1:400) for 30 min and then with a Strepatavidin / 
HRP complex (Dako, P0397, 1:500) for 30 min. Slides were then coloured with 3-
3’diaminobenzidine hydrochloride (DAB, Dako, K3468), counter-stained with hematoxylin 
and mounted with Eukitt medium for microscope observation. 
 For functional assessment of tumor lymphatic network and for in vivo visualization of 
sentinel lymph nodes [24] of xenografted mice (n = 5), semiconductor fluorescent nanocrystal 
Quantum Dots (Qdot® 705 ITK™, Invitrogen, Molecular Probes, ref. Q21561MP) were used. 
Mice bearing tumors were anesthetized with isofurane (1-3%) and 10 µl of Qdots (8 µM) 
were directly injected into the tumors. Drainage of Qdots from the tumor to sentinel lymph 
nodes was visualized 24 hours after Qdots injection by fluorescent imaging using a 
PhotonImager optical camera. 
   
Ultrastructure of tumor vasculature by transmission electron microscopy 
 Tumor xenografts excised at day 30 post cell injection in Rag-1 deficient mice were 
fixed for 1 hour at 4°C with 2.5% glutaraldehyde in a Sörensen 0.1 M phosphate buffer (pH 
7.4).  After postfixation for 30 minutes with 1% osmium tetroxide and deshydratation, 
samples were embedded into Epon (Luft, 1961). Ultrathin sections obtained with a Reichert 
Ultracut S ultramicrotome were contrasted with uranyl acetate and lead citrate. Observations 
were done with a Jeol 100 CX II transmission electron microscope at 60 kV. 
 
Analysis of tumor vaculature by fluorescent microscopy  
 Mice bearing tumors were euthanized between 4 and 6 weeks (in order to standardize 
the tumor volumes) after s.c. tumor cell injection. Functional tumor vasculature was 
visualized by intravenous injection of (FITC)-labelled Lycopersicon Esculentum (tomato) 
lectin and the vascular tree was maintained in an open state by perfusion with PFA as 
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described above excepting the following modifications: the vasculature was fixed by 
perfusion of 40 ml of PFA (120 mm Hg), for 4 minutes via the left ventricle and the blood-
exit incision was performed in the right atrium. Tumors were then harvested, fixed in 4% PFA 
at 4°C for 24 hrs, incubated in sucrose 30% / azide 0.1% / PBS at 4°C for 48 hrs, rinsed in 
PBS, embedded and frozen in OCT compound (Tissue-Tek). 
To visualize perivascular cells, thick frozen sections (100 µm) were rinsed in PBS, 
permeabilized in PBS / 0.3% Triton X-100 / 0.25% gelatin for 30 min at room temperature 
and incubated for 2 hrs in the permeating solution containing Cy3-conjugated mouse 
monoclonal antibody raised against anti-alpha-smooth muscle actin (SMA) (1:1,000, clone 
1A4, C6198, Sigma). Sections were then washed in PBS and mounted with Vectashield Hard 
Set Medium with DAPI (Vector Laboratories, Burlingame, CA, H-1400) for fluorescence 
microscopic observations. 
 
Vascular morphometric measurements 
Thick sections of xenografts expressing (n = 10) or not (n = 5) MT4-MMP were 
observed with a fluorescent microscope (Olympus) at 200-fold magnification. The whole 
surface of tumor sections was scanned and photomicrographed (50-100 / section). The mean 
vessel density was calculated by counting the number of intratumor blood vessels present 
either on the whole area sections or on the most vascularised area (“hot spots”) of the 
sections. The cross-sectioned area and the size distribution of the blood vessels were analyzed 
using ImageJ software (http://rsb.info.nih.gov/ij/). According to previous studies [23,25], one 
of the following diameter categories was assigned to each vessel : < 25 µm (small), between 
25 µm - 50 µm (medium) or ≥ 50 µm (large).  
In order to analyze the mural cells distribution around the blood vessels, an original 
computer-assisted quantification was developed by implementing an algorithm in MATLAB 
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software (http://www.mathworks.com/): concentric rings were drown all around the vessels 
by successive dilatation of vessels shape at similar intervals of distance. The densities of red 
pixels (mural cells) crossed by this grid were then calculated as a distance function from the 
green pixels (endothelial cells). Although the grids shown in figure 4 are simplified for a 
better visibility, the grids used for the quantifications were drawn at 3 concentric rings/µm.    
 
Evaluation of tumor vascular leakage 
 Six weeks post tumor cell injection, xenografted nude mice (n = 3) were anesthetized 
with isofurane (1-3%) and intravenously injected with 150 µl (2 mM in PBS) of 
AngioSense™ 680 vascular probe (VisEn Medical Inc, Woburn, MA, USA). Fluorescent 
signal of AngioSense was monitored in the mice 7 hours and 24 hours after the probe 
administration using a PhotonImager camera. Region of interest (ROI) were drawn on the 
tumour and a reference zone in the abdomen in order to measure the fluorescence intensity 
(cpm/mm2). The vascular leak in the tumour was quantified as the ratio fluorescence from the 
tumour / fluorescence from the reference.  
 
Statistical analysis 
Statistical differences between experimental groups were assessed using the non 
parametric Mann-Whitney test in which P-values < 0.05 (*) were considered as significant. 






MT4-MMP over-expression does not affect lymph node metastasis 
MT4-MMP overexpression in MDA-MB-231 cells has been previously associated 
with higher levels of lung metastases when subcutaneously injected into mice [18].  In order 
to determine whether this pro-metastatic effect of MT4-MMP could be related or associated to 
a higher lymphatic tumor cell dissemination, the presence of lymphatic vessels in the 
xenografts was first analysed by LYVE-1 immunostaining (Fig. 1 A, left panels). While some 
LYVE-1 positive lymphatic vessels were detected in the xenografts, mainly at the periphery 
of the tumor, no difference was evidenced between xenografts expressing or not MT4-MMP. 
The functionality of lymphatic vessels was then assessed by analysing the lymphatic drainage 
of fluorescent Quantum Dots (Qdot), 24 hours after their intratumoral injection (Fig 1 A, 
middle and right panels). A rapid and reproducible migration of fluorescent nanoparticules 
was observed in sentinel lymph nodes of mice. However, these nanocristals accumulated in 
regional (inguinal) and distal (axillary) lymph nodes independently of MT4-MMP status (Fig. 
1 A, right panels).  
To confirm by bioluminescence imaging (BLI) that MT4-MMP promotes lung 
metastasis from subcutaneous grafts, cells expressing MT4-MMP and luciferase or their 
control clones have been generated (Fig. 1 B and Fig. 2 A). We checked by RT-PCR and 
Western blot that luciferase expression did not affect MT4-MMP production (data not 
shown). Due to the high bioluminescence signal from the primary tumour, weak 
bioluminescence signal from micro-metastases were difficult to access directly in vivo. 
Therefore ex vivo analyses were also performed on lymph nodes and lungs recovered 8 weeks 
after subcutaneous injection of cancer cells (Fig. 1 B). Lung metastasis was clearly increased 
after the injection of cells expressing MT4-MMP compared with control cells (60 % versus 0 
%) (Fig. 1 B). However, no significant difference in the incidence of lymph node metastasis 
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was observed between MT4-MMP expressing or control cells (Fig. 1 B). Altogether, these 
data suggest that MT4-MMP expression improves lung metastasis but not lymphatic 
dissemination.  
 
MT4-MMP over-expression does not affect extravasation from the blood to the lungs 
To distinguish between an effect on primary invasion (fater subcutaneous injection) 
and extravasation from the bloodstream, cells expressing MT4-MMP and luciferase or their 
controls were alternatively injected via the tail vein. In these conditions, in sharp contrast to 
the xenograft model (Fig. 2 A), the percentage of animals with lung colonies was not 
influenced by MT4-MMP expression (100 % versus 80 % with MT4-MMP expressing or 
control cells, respectively) (Fig 2 C).  
To assess the histological severity of lung metastasis, Ki-67 immunostaining were 
performed on lung sections to detect human metastatic cells (Fig. 2 B, D) [18]. Metastatic 
nodules were scored according to the number of Ki-67 positive cells: severity-1 (< 3 cells), 
severity-2 (between 3 and 20 cells), severity-3 (>20 cells). As previously reported [18], the 
severity of metastasis was drastically increased by MT4-MMP expression after subcutaneous 
injection (Fig 2 B). In sharp contrast, after intravenous cell inoculation, neither the number 
nor the severity of lung metastasis was affected by MT4-MMP expression (Fig. 2 D).  
We have then evaluated the ability of cells to adhere and extravasate from blood 
vessels into the lungs of mice in a short-term assay. After intravenous injection of cells pre-
labelled with a red-fluorescent cell tracker (n = 10), lung vasculature was visualized 48 hours 
latter by perfusion with a FITC-conjugated lectin. Remaining adhering / extravasating tumor 
were detected in the lung of 100 % mice and no difference was observed between mice 
injected with MT4-MMP expressing cells (MT4 clones) or control cells (CTR clones) (Fig. 2 
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E). All these data support the notion that MT4-MMP does not affect the extravasation 
efficiency of cancer cells to the lungs.  
 
MT4-MMP over-expression affects intratumoral blood vessel size and perivascular cell 
distribution 
We next investigated the primary tumor vascular architecture by transmission electron 
and fluorescent microscopic analysis. As opposed to similarities in the ultrastructural features 
of endothelial cells, explicit differences were noted between the two experimental groups with 
regard to endothelial cell and pericyte interactions. As previously described in other types of 
tumors [23,25], basement membranes wrapping around tumor pericytes were abnormally 
thick, irregular and sometimes absent in both experimental conditions (data not shown). 
However, pericytes of xenografts expressing MT4-MMP were irregularly shaped, extended 
cytoplasmic processes and were loosely associated with endothelial cells (Fig. 3 A) in 
comparison with those of control xenografts which were apposed to endothelial cells (Fig. 3 
B). Interestingly, intravasation of tumor cells were observed in MT4-MMP expressing 
xenografts, in which tumor cells extended protrusions into the lumen of vessels (in 3 out of 25 
vessels observed)(Fig. 3 C). In contrast, in control xenografts, intravasation process was never 
detected and their vessels displayed a thick intact basement membrane supporting apposed 
endothelial (Fig. 3 D).  
Functional vascular tree of subcutaneous xenografts was then analysed by fluorescent 
microscopic observation of thick tumor sections. Tumor vessels washed free of blood were 
visualized by intraluminal staining with a FITC-conjugated lectin and perivascular cells were 
immunostained for alpha smooth muscle actin (SMA). Xenografts expressing MT4-MMP 
were characterized by enlarged blood vessels (Fig. 4 B) compared with control xenografts 
(Fig. 4 A).  To determine the distribution of blood vessel size, one of the following size 
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categories was assigned to each vessel according to their diameter: < 25 µm (small), between 
25 µm - 50 µm (medium) or ≥ 50 µm (large). In MT4-MMP tumors compared to control 
xenografts, the percentage of small vessels fell from 78 % to 58 % (P < 0.05) while those of 
medium and large-sized vessels rose from 18 % to 29 % (P < 0.05) and from 4 % to 13 % (P 
< 0.01) (Fig. 4 C). The density of large vessels was 2-fold higher (P = 0.01) in tumors 
expressing MT4-MMP as compared to control tumors (data not shown) whereas no 
significant difference in the total blood vessel density was observed between both conditions 
as assessed by quantification of the total number of vessels either present on the whole tumor 
section (Fig. 4 D) or on “hot spots” tumor areas (data not shown). However, an increase of the 
mean cross-sectioned blood vessel area (P = 0.002) was noticed in MT4-MMP expressing 
xenografts (Fig. 4 E). This vascular enlargement further confirms the effect of MT4-MMP 
expression on vessel architecture rather than on vascular density. 
In order to quantify the detachment of pericytes observed in the enlarged vessels of 
tumor expressing MT4-MMP (Fig. 4 A, B), we set up a computer-assisted quantification 
using a grid of SMA-positive cell distribution (Fig. 4 A, B ; right upper corners). More than 
800 and 400 blood vessels from 10 MT4-MMP-expressing and 5 control xenografts, 
respectively, were analyzed. Perivascular cell distribution calculated as a distance function 
from the tumor blood vessels, shows that the density of “detached” mural cells present at 5 
µm, 10 µm or 15 µm from endothelial cells were 2-folds higher in MT4-MMP expressing 
tumors compared to control xenografts (Fig. 4 F). These data reflect impaired pericytes-
endothelial cells interactions which is consistent with the transmission electron and 




MT4-MMP effect on blood vessel morphology is associated with an increase of vessel 
leakage 
 In order to verify whether the strong effect of MT4-MMP on blood vessel architecture 
could increase the permeability of vessels, we have used AngioSense680 vascular probe 
which is a fluorescent polymeric macromolecule of 250 kD. Due to its high molecular size, 
this probe remains in the blood for a long time and can extravasate into tissues containing 
blood vessels that have large gaps between endothelial cells. This phenomenon, called 
“Enhanced Permeability and Retention” (EPR) effect, is well known to target tumour 
containing leaky blood vessels [26,27].  This probe was therefore used to assess in vivo 
vascular leak of blood vessels in the xenografts expressing or not MT4-MMP. Seven hours 
after its intravenous injection, the AngioSense680 was uniformly distributed in the 
vasculature of all mice bearing tumors and no difference of fluorescence could be observed 
between xenografts either expressing or not MT4-MMP (Fig. 5 A and C). However, 24 hours 
after injection, the probe had extravasated and strongly accumulated in tumor areas of MT4-





The direct implication of MMPs in tumor progression is extensively documented and 
an increasing number of evidences shows that MMP could have a much broader role in the 
metastatic process than initially expected, including their intervention in key steps of the 
metatastatic cascade such as angiogenesis, intravasation, extravasation and 
initiation/maintenance of secondary tumor growth [9,28,29]. However, to date, very few 
MMPs (MMP-7, MMP-8, MT1-MMP, MT4-MMP) have been described to directly modulate 
the dissemination of cancer cells at distance from a primary tumor, as assessed in spontaneous 
models of metastasis (subcutaneous xenografts) [18,30-32]. Moreover their mechanisms of 
action and the specific steps of the metastatic cascade affected by these MMPs are unknown. 
In the present study, by using different approaches of immunohistological, 
ultrastructural and in vivo imaging analyses, we provide evidence that the pro-metastatic 
effect of MT4-MMP occurs by affecting the hematogenous route of tumor cell spreading 
rather than the lymphatic way. Indeed, we demonstrate that MT4-MMP does not affect the 
incidence of lymph node metastasis nor the functionality of tumor lymphatic network. In 
contrast, the overexpression of MT4-MMP led to higher spontaneous but not experimental 
lung metastasis. It did not detectably affect tumor cell extravasation or early implantation into 
lung but increased the hematogenous dissemination of tumor cells from a primary 
subcutaneous tumor. Thus, MT4-MMP affects more likely the intravasation process than later 
steps of the metastatic dissemination. In agreement with previous reports, intravasation is 
described as one of the rate-limiting steps of the metastatic process [9,33] while extravasation 
is qualified as a rather efficient process [28,34]. This impact of MT4-MMP on metastasis 
could not be ascribed to a clonal effect since similar results were obtained by using 3 different 
clones over-expressing MT4-MMP [18]. In addition, in the present study, the generation of 
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cells expressing luciferase gave rise to similar promoting effect on the metastatic 
dissemination, without affecting MT4-MMP production. 
Vascular architecture of primary tumors expressing or not MT4-MMP was explored 
by transmission electron and fluorescent microscopy. Although MT4-MMP expression in 
xenografts did not affect the total blood vessel density, it was associated with an enlargement 
of intratumor blood vessels with an increase of the mean vessel cross-sectioned area and the 
density of large vessels. Interestingly, a detachment of mural cells from the endothelial cells 
as well an increase of macromolecules leakage was detected in the tumors expressing MT4-
MMP. Based on these findings, the metastasis promoting effect of MT4-MMP could be 
explained by its effects on blood vessel architecture making them more permissive to tumor 
cells intravasation. This is consistent with the observations of intravasating tumor cells in 
xenografts expressing MT4-MMP by electron transmission microscopy. Hence, the larger, 
destabilized and leaky blood vessels observed in xenografts expressing MT4-MMP could lead 
to a higher level and a more efficient intravasation of tumor cells into the blood vasculature. 
In agreement with this concept, a relation between the blood vessel architecture and the 
development of metastasis has been reported. Mouse models with deficiencies in pericytes / 
endothelial cells interactions [35,36] and genetic engineered mice with blood vessel structural 
fragilities [37] develop more hematogenous metastasis. The presence of pericytes and their 
interaction with endothelial cells are thought to limit tumor metastatic dissemination as 
demonstrated by studies using mouse tumor models with loss / gain of NCAM or PDGF-B 
lacking the motif necessary to its endothelial retention [35,36]. Therefore, this study reports 
for the first time, the implication of MT4-MMP in tumor cell intravasation and its effect on 
blood vessels integrity. Such a novel role for MT4-MMP in tumor blood vessel architecture is 
consistent with its expression in various smooth muscle cells [14] or in endothelial and 
perivascular cells of human endometrium in vitro [38] and  in vivo during menstrual phases 
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associated with high angiogenic activities [39]. Our paper sheds light on the contribution of 
MT4-MMP in metastatic dissemination in agreement with the relationship recently 
established between MT4-MMP expression and the transition from pre-invasive to invasive 
breast cancer [40]. 
 Given the importance of the ECM deposition in blood vessel formation / stabilization 
and the broad range of ECM substrates cleaved by MMPs [3,4], it is not surprising that one of 
theses proteases could affect tumor blood vessel morphology. However, MT4-MMP is one of 
the lest efficient MMPs toward ECM protein degradation and its catalytic domain is unable to 
cleave important blood vessel basement membrane components such as type-IV collagen, 
fibronectin, laminin and decorin  [19, 41, 42]. Nevertheless, new functions recently emerged 
for MMPs including their involvement in pericytes recruitment [43] through (i) a mobilization 
of bone marrow derived progenitors [44], (ii) a regulation of vessel wall architecture by 
modulating PDGF-B / PDGFRβ signaling pathway [45] and/or (iii) an alteration of pericyte 
adhesion. For instance, MT1- and MT3-MMP are able to decrease the integrin-mediated cell 
adhesion by cleaving focal adhesion kinases in vascular smooth muscle cells [46]. However, 
in our study, MT4-MMP expressed by cancer cells did not affect their adhesion in vitro to 
different matrices including laminin, fibronectin, type-I collagen, gelatin, endothelial cells 
layer or their ECM deposit (data not shown). MT4-MMP could affect vessel integrity through 
different mechanisms. For instance, it could contribute to the shedding of molecules more 
specifically implicated in pericytes / endothelial cells adhesion as it has been demonstrated for 
other MMPs [3,47].  In order to determine the impact of MT4-MMP on endothelial cell 
differentiation and/or endothelial cell to pericyte interactions, monocultures, as well as co-
cultures of these different cells types including tumour cells or medium conditioned by 
tumour cells were performed on matrigel. All these in vitro attempts failed to reproduce the in 
vivo observations. This fits with our previous work showing that MT4-MMP production did 
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not affect tumour cell properties in vitro [18]. These information suggest that MT4-MMP 
exerts its effect through cellular or extracellular factor(s) present in the tumour 
microenvironment, but absent in vitro. In an attempt to elucidate the molecular mechanisms of 
MT4-MMP action, we have searched for modulation of the levels of different major 
angiogenic regulators in xenografts expressing or not MT4-MMP (data not shown). Neither 
VEGF, ANG-1, ANG-2, TIE-1, TIE-2, NRP-1, PDGF-B, PDGFR-B, HGF, AKT-1, PAI-1, 
MMP-2, MMP-9, MT1-MMP nor PECAM mRNA levels were affected by MT4-MMP 
expression as assessed by RT-PCR analyses (data not shown). In addition, no difference in the 
production of key angiogenic modulators (VEGF, PDGFR, FGF and their receptors) was 
detected at the protein levels by antibodies arrays. However the mRNA expression of human 
thrombospondin-2 was 3-fold decreased in xenografts expressing MT4-MMP compared to 
control xenografts (P = 0.002) (data not shown). Interestingly, a reduced expression of this 
antiangiogenic factor has already been associated with impairment of vascular integrity and 
permeability in mouse models [48] and its genetic deletion in TSP-2 knock-out mice favors 
tumor growth, metastasis and angiogenesis [49,50]. Altogether, these data suggest that the 
downregulation of TSP-2 expression observed upon MT4-MMP production could, at least 
partly, account for the impairment of the vascular integrity and thereafter for the increased 
metastatic dissemination. 
In conclusion, during the last decade, the contribution of various MMPs to both early 
and late events of the metastatic process has emerged. However, the role of GPI-anchored 
MT-MMP has been shadowed by a focus on soluble MMPs and MT1-MMP. The present 
results provide evidence for an implication of the GPI-anchored MT4-MMP in the 
intravasation rather than in the extravasation step of metastatic process, through the disruption 
of vascular integrity in primary tumors. It also underlies the impact of MT4-MMP on 
hematogenous, but not lymphatic spread. 
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Figure 1. Effect of MT4-MMP on tumor lymphatic network and lymph node metastasis. The 
tumor lymphatic network (A) and the presence of lymph node metastasis (B) were analysed in 
athymic nude mice after subcutaneous injection of MDA-MB-231 breast cancer cells 
expressing (MT4-xenografted mice ; upper panels) or not (CTR-xenografted mice ; lower 
panels) MT4-MMP. A : Lymphatic vessels were detected at the interface between the tumors 
(T) and the host stroma (S) by LYVE-1 immunostaining of xenograft sections (left panel). 
Functionality of tumor lymphatic network was assessed by lateral (middle panel) and ventral 
(right panel) visualization of sentinel lymph nodes 24 hours after intratumoral injection of 
fluorescent nanocrystals (Qdot). Black arrows indicate accumulated Qdot particules in the 
regional (inguinal ; I) and distal (axillary ; A) lymph nodes. B : The presence of regional 
(inguinal ; I) and distal (axillary ; A) lymph node (LN) metastases as well as lung metastases 
were detected by bioluminescent analysis of the luciferase reporter gene in each organ ex vivo. 
Percentage represents the incidence of mice with detectable metastasis in each organ (n=10).  
 
Figure 2. Effect of MT4-MMP on lung metastases. MDA-MB-231 breast cancer cells 
expressing (MT4 clones) or not (CTR clones) MT4-MMP were injected into immunodeficient 
mice either subcutaneously (spontaneous model of metastasis : A and B) or intravenously 
(experimental model of metastasis : C, D ; E). A-D : After 6 weeks of incubation, 
subcutaneously- (A, B) and intravenously- (C, D) injected mice were analysed for the 
presence of lung metastases by in vivo bioluminescent detection of luciferase reporter gene 
(A, C) and by histological analyses of lung sections after Ki-67 immunostaining (B, D). A, C: 
numbers represent the percentage of mice with lung metastases. B, D: Severity of metastasis 
was determined by counting Ki-67 positive cells in metastatic foci and scored as: severity-1 
(less than 3 stained cells), severity-2 (3 to 20 cells) or severity-3 ( more than 20 stained cells) 
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(B, C). E : Cells pre-labelled with red-fluorescent CMTPX Cell Tracker were intravenously 
injected. After 48 hours, extravasating cells (in red) from the FITC-lectin-labelled blood 
vessels (in green) were analysed by fluorescent microscopic observation of lung sections 
counterstained with DAPI (in blue) (scale bar = 50 µm). The number of tumor cells was 
counted  on 20 microscopic fields (X400). Results are expressed as the mean of each 
experimental group (n=10). Error bars represent SE. *P < 0.05; ***P < 0.001. 
 
Figure 3. Transmission electron micrographs of blood vessels in breast cancer xenografts. 
Transfectants were subcutaneously injected into Rag-1 immunodeficient mice. After 4 weeks 
of incubation, ultrathin sections of xenografts expressing (Xenograft MT4; A, C) or not 
(Xenograft CTR ; B, D) MT4-MMP were analyzed with a Jeol 100 CX II transmission 
electron microscope at 60 kV. A, B: Pericytes (p) are present in both conditions but are 
irregularly shaped, extend more frequent cytoplasmic processes (black arrows) and are 
loosely associated with endothelial cells (ec) in tumors expressing MT4-MMP (A) compared 
to control tumors (B). C, D: Intravasating tumor cells (black arrow-head) were preferentially 
observed in the lumen (l) of blood vessels of xenografts expressing MT4-MMP (C) in contrast 
with control xenografts where tight associations between endothelial cells (ec) were observed 
(D). Rc, red blood cell. A and B at 8,000-fold magnification (scale bar = 2 µm). C and D at 
13,000-fold magnification (scale bar = 1 µm). 
 
Figure 4. Effect of MT4-MMP on tumor blood vessel morphology and perivascular cells 
distribution. Functional vascular tree of xenografts expressing or not MT4-MMP was 
visualized by intravenous injection of a (FITC)-labelled lectin in tumor-bearing mice (n = 10). 
A, B: Fluorescent photomicrographs of representative sections of xenografts expressing (A) or 
not (B) MT4-MMP and showing an enlargement of FITC-lectin-labelled blood vessels (in 
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green) as well as alpha-SMA positive mural cells (in red) distribution around the vessels 
(scale bar = 100 µm). C, D, E: The diameter, the density and the area of blood vessels (vsls) 
of thick tumor sections from xenografts expressing (black histograms) or not (white 
histograms) MT4-MMP were assessed using ImageJ software. C : The distribution of the 
lumen of tumor blood vessels is expressed as the percentage of blood vessels observed on the 
whole tumor sections according to the respective diameter categories (small : < 25 µm ; 
medium : ≥ 25 µm and < 50 µm ; large : ≥ 50 µm). D: Mean blood vessel density observed on 
the on the highest vascularised regions (hotspots). E: Mean size of the blood vessels assessed 
by measurement of their cross-sectioned area (mean area/vsl). Error bars represent SE. *P < 
0.05 ; **P < 0.01. F: Perivascular cells distribution in function of the distance from the tumor 
blood vessels. The pixel density of alpha-SMA positive cells at 5 µm from endothelial cells is 
still 2-folds higher in MT4-MMP condition (black squares) compared to control condition 
(white squares). Examples of quantification grids used to measure the perivascular cell 
distribution are shown in the right upper corners of photomicrographs A and B.  
 
Figure 5. Vascular leakage of breast cancer xenografts expressing MT4-MMP. The vascular 
permeability of subcutaneous xenografts expressing (MT4) or not (CTR) MT4-MMP was 
assessed by injecting intravenously a fluorescent probe AngioSense™ 680 (n=5). A, B : 
Representative distribution of fluorescent macromolecule remaining in the mice 7 hours (A) 
and 24 hours (B) after intravenous administration. Tumors are delineated by dotted circle. C: 
Quantification of fluorescence ratio tumour / surrounding abdominal tissue. Error bars 
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